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Summary
Objective: Several genome-wide scans have revealed an osteoarthritis (OA)-susceptibility locus on chromosome 11q in close proximity to the
low-density lipoprotein receptor-related protein 5 (LRP5) gene. The regulation of bone mass is under the control of LRP5 and since increased
bone mass is thought to play a role in the pathology of OA we examined LRP5 polymorphisms and haplotypes to determine if variants of this
locus may predispose to OA.
Methods: A UK control population of 187 individuals was examined for ﬁve commonly occurring polymorphisms against a cohort of 158 DNAs
from patients with knee OA. An additional UK cohort was also examined to conﬁrm the ﬁndings of the ﬁrst study; this second group consisted
of 110 knee OA patients. Haplotype analysis was also performed on patient and control DNAs.
Results: A study of individual polymorphisms revealed no association with disease. However, haplotype analysis of the initial two populations
revealed a common haplotype (C-G-C-C-A) that provided a 1.6-fold increased risk of OA (PcZ 0.021). The data obtained from the second
cohort conﬁrmed the initial ﬁndings, with a 1.6-fold increased risk observed within this cohort for the risk haplotype (PZ 0.012).
Conclusions: A closer investigation of LRP5 and associated Wnt signalling molecules in OA will help determine disease aetiology and the
development of novel treatment strategies that speciﬁcally target the bone compartment.
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Osteoarthritis (OA) affects an estimated 5 million people in
the UK1 and represents the most common form of joint
disease2. The condition is characterised by subchondral
and cancellous bone sclerosis, osteophyte growth, cartilage
loss and joint space narrowing. The widely held belief that
OA is a disease of cartilage has, particularly in recent years,
been a subject for debate3,4, and several researchers have
postulated that bone changes may account for subsequent
joint deterioration and development of OA5e10. However,
whether bone matrix composition and metabolism are
actually altered in OA has only emerged from more recent
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2005.60investigations, for example the studies on OA osteoblas-
ts11e15 and OA bone matrix16e19. Collectively these recent
works add further support of a role for bone in OA aetiology;
primary OA osteoblasts behave differently to healthy
controls, e.g., marked basal and vitamin D induced ex-
pression of osteocalcin11. In addition, bone matrix turnover
is very high and the collagen hypomineralised16,17, ﬁndings
that may explain some of the changes observed for the
biomechanical properties of OA bone18,19.
In addition to the changes observed for bone matrix
composition and metabolism, individuals with OA exhibit
striking increases in bone mass for both affected sites, such
as the hip or knee, as well as non-synovial sites, such as
the lumbar spine20; the literature supports a systemic
increase in bone mass in patients who have OA. Indeed
the general, but still controversial opinion, is that higher
bone mass increases the risk of developing OA20e22. This
concept is strengthened by the increased incidence of OA
in subjects who present with osteopetrosis23, a condition
characterised by greater bone mass. The possibility that8
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deterioration and progression to OA was ﬁrst put forward
by Radin and colleagues8,9. They proposed that stiffening of
the subchondral bone would result in increased sheer
stresses at the boneecartilage interface, culminating in
cartilage splitting and erosion. This mechanism was
serendipitously supported by the replacement of subchon-
dral bone matrix with much stiffer polymethylmethacrylate
resin in a canine model of hip arthroplasty24; modiﬁed
femoral heads displayed the classic signs of cartilage loss
consistent with advanced OA, whereas contralateral control
hips remained unaffected. The authors concluded that joint
deterioration was probably a consequence of changing the
stiffness of the subchondral material.
Furthermore, in OA bone there is an overall increase in its
metabolism25,16,17 and an increased expression of osteo-
genic factors such as transforming growth factor-b and
insulin-like growth factors11,17. These local growth factors
also show increased expression in those regions, for
example, the iliac crest26, which are deemed not to be
‘‘OA sites’’. The study of spontaneous OA in animal models
such as the Macaque27 and guinea pig28,29 have provided
compelling evidence for bone thickening prior to cartilage
tissue loss. Collectively, increased bone mass and/or
metabolism, particularly at synovial joints may predispose
subjects to OA.
It is well established that OA is a disease with a large
multigenic component. Interestingly, evidence has emerged
that supports OA-susceptibility loci to chromosome 11q12-
1330,31, a region well known to harbour genes controlling
bone mass32,33. One such gene encodes for the low-
density lipoprotein receptor-related protein 5 (LRP5), a co-
receptor for Wnt/b-catenin signalling34. It is now known that
LRP5 is required for osteoblast proliferation35,36 and
possibly the prevention of osteoblast apoptosis37. In
a recent review of the literature38, it is becoming clear that
LRP5/Wnt signalling is central for post natal bone de-
velopment and adult bone accrual making LRP5 an exciting
candidate for further study in the context of musculoskeletal
diseases, including OA.
We propose that LRP5 may represent a potential
candidate gene in the predisposition of OA due to its strong
association with bone mineral density (BMD)38. Loss-of-
function mutations in LRP5 result in osteoporosisepseudo-
glioma syndrome (OPPG), an autosomal recessive
disorder35. Conversely a gain-in-function mutation, for
example a G171V point mutation, results in elevated bone
mass, enhanced alkaline phosphatase activity and raised
active osteoblast number37. Furthermore, mutation analysis
of families and patients has revealed at least 19 LRP5
sequence variants of which six are thought to result in
a high bone mass phenotype39. Given the compelling
association of high bone mass and OA, LRP5 certainly
warrants closer investigation into this debilitating disease.Methods
PATIENTS AND CONTROLS
OA Patients (nZ 268) were studied from two UK centres:
Bristol (nZ 110, 45 male and 65 female Caucasians: mean
ageZ 62; median ageZ 63); and London (nZ 158, 41
male and 117 female Caucasians: mean ageZ 71; median
ageZ 71). All patients had knee OA as deﬁned by the
American College of Rheumatology (ACR) criteria with at
least grade 2 radiological change. Radiographic diagnoses
were performed by the same consultant rheumatologist in
all cases. Control subjects were 187 (94 male and 93
female) unrelated healthy Caucasian volunteer blood
donors from South West England. Informed consent was
obtained with appropriate local ethics committee approval.
Genomic DNA was isolated from peripheral blood leuco-
cytes using a salting out procedure40.
SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) GENOTYPING
Five LRP5 SNPs from LocusLink (http://www.ncbi.nlm.
nih.gov/LocusLink/) were selected for the study: rs491347,
rs583545, rs667126, rs314751, and rs689179. These were
chosen to represent the 3#-end of the LRP5 gene, including
two haplotype tag (ht) SNPs represented in the International
HapMap project (rs491347, htSNP 34, block 4; and
rs583545, htSNP 38, block 5), see http://www.hapmap.org.
In view of the relatively small number of patients, three other
appropriate 3#-SNPs were chosen with minor allele
frequencies above 0.25 to generate an appropriate distri-
bution of haplotypes to provide sufﬁcient statistical power
for the association study. For each polymorphic locus to be
analysed, polymerase chain reaction (PCR) ampliﬁcations
were set up in a total volume of 20 ml containing 200 ng
genomic DNA, 0.1 Unit Taq polymerase (Abgene, Epsom,
Surrey, UK), 0.05 mM of each PCR primer (Table I), 2 ml of
10! reaction buffer [160 mM (NH4)2SO4, 670 mM Tri-
seHCl (pH 8.8 at 25(C), 15 mM MgCl2, 0.1% v/v Tween-20
(Ameresco Chemicals, Anachem, Luton, UK)], 0.8 ml DNA
polymerisation mix (Abgene). Ampliﬁcation was carried out
in a PTC-100 thermal cycler (MJ Research Inc., Waltham,
MA, USA) using cycle parameters of: 95(C for 5 min (initial
denaturation), then 35 cycles of: 95(C (30 s), annealing
temperature (Ta) (see Table I) (40 s) and 72(C (30 s); with
a ﬁnal extension for 5 min at 72(C.
PCR-single strand conformational polymorphism was
employed for the purpose of genotyping using poly-
acrylamide gel electrophoresis as described41 in 12%
nondenaturing polyacrylamide gels (Protogel, National
Diagnostics, Atlanta, GA, USA) containing 1! Trise
borateeethylenediaminetetraacetic acid (TBE) buffer.
Electrophoresis was carried out at 300 V for 150 min on
a triple-wide minigel system (CBS Scientiﬁc Company Inc.,
Del Mar, USA). DNA was visualised by staining for 10 minTable I
LRP5 polymorphisms analysed in this study
dbSNP rs#
cluster I.D.
Gene position Allele frequencies PCR primers (5#e3#) Ta
rs491347 LRP5 intron 8 CZ 0.31, TZ 0.69 FZAACACCTGAACCAACGGAG RZCGCTTTTCTGGTAAGCTGGA 60
rs667126 LRP5 intron 11 AZ 0.68, GZ 0.32 FZGTGCGTCCTTGTGTTCACC RZCCAGCACTGTGCCTGATACA 62
rs583545 LRP5 intron 11 CZ 0.27, TZ 0.73 FZACCCCTGCCACACACATATC RZGCTTGTGTCCATCCTGGTTT 61
rs689179 LRP5 intron 12 CZ 0.26, TZ 0.74 FZCATGATCGAGTCGTCCAACA RZGGACAACTCCCACAGCAGAG 62
rs314751 LRP5 intron 12 AZ 0.32, GZ 0.68 FZGTTCAGGATCCCCCAGAGAT RZCCTGTTGCTGTGTGACTTGG 61
The dbSNP rs reference number is provided with the location of each SNPs within LRP5 and allele frequencies from the control population.
PCR primer sequences are provided with the Ta for PCR indicated.
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gels were imaged using a Kodak EDAS 120 digital camera.
HAPLOTYPE AND DISEASE ASSOCIATION ANALYSIS
Allele frequencies were estimated by gene counting and
potential deviation in HardyeWeinberg equilibrium was
tested using the c2 test with 1 df. Haplotypes were
constructed from genotypic data using the PHASE 2.0
software platform42,43. Haplotypes with an observed fre-
quency of less than 0.02 were analysed as a combined
group. To identify potential risk or protective haplotypes,
haplotype frequency comparisons between control and OA
patients were performed using haplotypic odds ratios (OR)
with Cornﬁeld 95% conﬁdence intervals (CI). Pearson’s c2
test or Fisher’s exact test were used to determine un-
corrected P-values and corrections were made for multiple
comparisons (Pc) where appropriate.
Results
ANALYSIS OF LRP5 GENE POLYMORPHISMS
IN CONTROL DNAS
Genotyping of 187 controls DNAs for the ﬁve common
LRP5 polymorphisms: rs491347, rs583545, rs667126,
rs314751, and rs689179 were carried out (see Table I for
allele frequencies). Examination of the data using PHASE
2.0 analysis resulted in a total of 13 haplotypes, although
90% of controls comprised three predominant haplotypes
due to the high levels of linkage disequilibrium (LD) in the
region examined (Table II).
POLYMORPHISM OF THE LRP5 GENE
AND ASSOCIATION WITH OA
One hundred and ﬁfty eight DNAs derived from a London-
based centre of patients with knee OA (at least grade 2 on
the ACR scale) were genotyped for the ﬁve polymorphisms
examined in the control population. The genotype frequen-
cies of the two populations were analysed using Pearson’s
c2 test and revealed no association between each poly-
morphism and OA. All genotype results were in Hardye
Weinberg equilibrium. Haplotype analysis was carried out
as with the control DNAs, revealing the presence of eight
haplotypes within the London OA cohort. All PHASE-
generated posterior probabilities for reconstructed haplo-
types were O0.9. Comparison of haplotypes between the
control and OA cohorts identiﬁed a common haplotype
(C-G-C-C-A) with a signiﬁcantly increased frequency in the
OA population (ORZ 1.6, CIZ 1.12e2.29; PZ 0.0069;
PcZ 0.021; Table II). Upon stratiﬁcation for gender, the
association remained within the female OA group
(ORZ 1.72, CIZ 1.06e2.78; PZ 0.019), although waslost within the male group, possibly due to low numbers of
this population (nZ 41).
To verify these results in a different population, an
additional study was carried out in a cohort of 110 DNAs
from a Bristol-based knee OA population. As with the
London OA cohort, there was no association between
single genotypes and OA, however, when the PHASE
haplotypic data were examined, the correlation that was
observed previously was conﬁrmed in this cohort. The C-G-
C-C-A haplotype was present at a signiﬁcantly higher
frequency than observed in the control population
(ORZ 1.62, CIZ 1.09e2.40; PZ 0.012).
Discussion
Osteoarthritic subjects often present with a systemic
increase in bone mass, suggesting that increased pro-
duction of bone may predispose to OA, particularly at
synovial sites, where increased bone content could be
sufﬁcient to precipitate the changes in cartilage that
ultimately contribute to joint failure. A potential candidate
that may help explain the increased bone mass in OA is
LRP5, a single span transmembrane protein belonging to
the low-density lipoprotein receptor family34.
LRP5 contains 23 exons and spans 160 kb of the
genomic sequence on chromosome 11q13.444. Such a large
region inevitably contains a signiﬁcant level of polymor-
phism, and genetic association studies of this nature require
the use of haplotypic analysis. Indeed, a study by Twells
et al.45 has examined the level of LD between LRP5
polymorphisms, characterising the presence of common
haplotypes. They identiﬁed three conserved regions of LD
throughout the gene, separated by recombination hot spots:
intron 1, intron 3 to intron 5, and intron 5 to intron 7.
To ascertain whether the LRP5 gene acts as a suscep-
tibility locus for OA, we examined a population of 158 knee
OA patients from London for ﬁve common polymorphisms
within the LRP5 gene; each contained within the largest
haplotype block (exon 7 to exon 23). Single polymorphisms
provided no correlation with disease status, but when
analysed as a group, a common haplotype (C-G-C-C-A)
was evident, which provided a 1.6-fold increased risk of OA.
A further study using a 110 knee OA cohort from Bristol
conﬁrmed these ﬁndings, again with a 1.6-fold increased
risk with the susceptibility haplotype. Given the relatively
small patient cohort sizes, the ﬁndings presented provide
a preliminary indication of an association between this
common LRP5 haplotype and OA. Further studies will be
required in order to conﬁrm the data in larger cohorts and
from other centres. Although we do not have these data it
will be pertinent to obtain information concerning body mass
index in view of the strong association of knee OA in
overweight populations. Because LRP5 not only regulates
adult bone accrual but also lipid metabolism34 a similarTable II
LRP5 haplotypes in control and OA populations
Haplotype Controls London knee OA Uncorrected P-value Bristol knee OA Uncorrected P-value
T-A-T-T-G 238 193 0.488 129 0.226
C-G-C-C-A 81 97 0.0069 68 0.012
C-G-T-T-A 16 5 0.04 5 0.958
Others 39 21 18
Total 374 316 220
Uncorrected P-values are provided in the table (see text for corrected P-values).
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strengthen a role of LRP5 in skeletal rather than lipid
metabolism per se.
Although it is generally agreed that OA is multifactorial,
the data presented support further studies into LRP5 in the
context of OA aetiology since it may be linked to
compromises in bone accrual and/or turnover. Bone
represents the major component of joint tissues, and the
tightly co-ordinated process of bone remodelling is crucial
for the maintenance of healthy joint competence and
architecture. If the process of bone metabolism and
turnover are disrupted, skeletal disorders including osteo-
porosis (OP) and osteopetrosis can occur. It is becoming
clearer that both bone architecture and metabolism are
profoundly altered in OA, and the subchondral bone
compartment, in particular, is involved in the pathogenesis
of OA16,17,4.
There is strong evidence that the pathology of OA is
related to bone density20e23. Indeed, the inverse relation-
ship between the development of OP, a disease of low bone
density, and OA, is well documented26. Previous research
has implicated the vitamin D receptor (VDR) alleles in
predicting BMD45, and several research groups have
analysed polymorphic markers in this gene for OA
association but with varied results. Indeed, the extent of
the role of VDR polymorphisms in bone density has now
been brought into question46,47. Genome-wide scans
amongst OA probands have suggested a link close to
chromosome 11q12-1330,31, and proposed that this ﬁnding
may be related to the location of a high bone mass gene.
Interestingly, this correlates with the location of the LRP5
gene, situated on chromosome 11q13.4. In light of recent
developments into OA aetiology we sought to focus our
attention on LRP5 because of its strong association with
bone accrual; loss-of-function mutations in LRP5 result in
OPPG35, whereas gain-in-function mutations result in
elevated bone mass, enhanced alkaline phosphatase
activity and raised active osteoblast number37. Mutation
analysis of families and patients has revealed at least 19
LRP5 sequence variants of which six are thought to result in
a high bone mass phenotype39. It is now established that
LRP5 is involved with osteoblast proliferation and may have
a role in the regulation of osteoblast apoptosis35e37. In
osteoblasts, LRP5 acts as a co-receptor for Wnt/b-catenin
signalling and it is now known that Wnt signalling is of
critical importance in skeletal differentiation48. During the
course of our investigation Loughlin and colleagues49
identiﬁed functional variants within the secreted frizzled-
related protein 3 (sFRP3) gene in women with hip OA.
These particular ﬁndings are of enormous signiﬁcance
since they provide further evidence of a role for Wnt
signalling in the development of OA; sFRP3, by binding to
Wnt5a blocks the noncanonical Wnt pathway50. The sFRP3
variant (Arg324Gly) identiﬁed by Loughlin et al. is unable to
antagonise Wnt signalling, the result of which is postulated
to predispose subjects to getting OA. Although sFRP3 is
restricted to cartilaginous tissue, the study by Loughlin
et al., together with our ﬁndings, strengthen the need to
examine the Wnt signalling pathways in situations of
musculoskeletal abnormality.
As with most signalling systems there are many adaptor
and substrate molecules that serve to regulate and/or
integrate multiple cellular signalling networks. Such com-
plexities are true of osteoblast Wnt signalling and the
associative changes with bone accrual and disease51. It will
be interesting to see if some of the LRP5 adaptor/substrate
molecules and/or interactions with other proteins areaffected in subjects predisposed to getting OA. For
example, Dickkopf 1 (DKK1), the endogenous antagonist
of LRP5 canonical signalling, is unable to antagonise the
G171V LRP5 mutant, a ﬁnding that may help explain the
high bone mass phenotype in subjects with this mutation52.
To date no studies have been undertaken to examine
whether DKK1 is expressed during bone development or
whether the levels of DKK1 are altered in subjects with OA.
Wise, by interacting with LRP5, antagonises Wnt/b-catenin
signalling and is also capable of antagonising bone
morphogenetic protein signalling34. Of further signiﬁcance
is the striking ﬁnding that ablation of the Wnt antagonist,
sFRP1, results in prolonged and enhanced trabecular bone
accumulation in adult mice but with no effect on other
tissues53. Clearly there are several key branches off a single
signalling cascade that are central to skeletal development
and turnover that could be the subject of further study in
OA. Some of these components, e.g., Wise, DKK1 and
sFRP1 could be investigated in OA given the importance of
bone in the development of this disease. Collectively these
studies should help disentangle the mechanism of disease
initiation and progression and shed further light into the role
played by bone in OA aetiology.
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